The present disclosure is related to dosage strategies for the treatment of CNS cancers with proteasome inhibitors (e.g., marizomib). For instance, the disclosure is related to strategies in which a proteasome inhibitor (e.g., marizomib) is administered at the same or higher dosage even after a subject has experienced a CNS-related adverse event.
Use Of Marizomib For The Treatment Of Central Nervous System (Cns) Cancers
The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.
Rita Kilcoyne, Ann Kelly, Margo Stults, Jay Arbetman, Howard Mack, Kathy Klotz, Julie Henke, Bill Abell, Connie Tallman, Virginia Leider, Steve Kammann
Biography:
After GBN I went to NIU then transferred to UofA in Tucson. It was there that I ran ...